Panhypopituitarism and diabetus insipidus in a patient with primary central nervous system lymphoma
Malaise, Olivier ; FRUSCH, Nicolas ; BECK, Emmanuel et al
in Leukemia & Lymphoma (2012), 53(12), 2515-16Detailed reference viewed: 36 (8 ULg)
Toxoplasma encephalitis after autologous stem cell transplantation.
; ; LAYIOS, Nathalie et al
in Leukemia & Lymphoma (2007), 48(1), 201-3Detailed reference viewed: 9 (0 ULg)
Association between Epstein-Barr virus and Hodgkin's lymphoma in Belgium: A pathological and virological study
; Bonnet, Christophe ; et al
in Leukemia & Lymphoma (2007), 48(7), 1323-1331
The association between Epstein-Barr virus (EBV) and classical Hodgkin's lymphoma (cHL) varies according to the geographic location. In this work we sought to characterize EBV involvement in a series of ... [more ▼]
The association between Epstein-Barr virus (EBV) and classical Hodgkin's lymphoma (cHL) varies according to the geographic location. In this work we sought to characterize EBV involvement in a series of 111 cHL cases diagnosed in Belgium. The overall prevalence of EBV infection detected by in situ hybridization in Reed-Sternberg cells was 33%. EBV positivity correlated with older age at diagnosis (454 years; p = 0.01), mixed cellularity subtype (p = 0.000001), male gender (p = 0.004) and tended to be associated with higher clinical stage (III/IV; p = 0.02). The molecular features of the virus in EBV-positive cHL were studied by comparison with a series of reactive tonsils. A 30-bp deletion within the LMP-1 gene was in 15/28 (53.6%) EBV-positive cHL cases, and in 41.7% of reactive tonsil samples. This variant did not correlate with any clinical or pathological feature. The EBV strain was type A in all cHL and reactive samples. [less ▲]Detailed reference viewed: 13 (0 ULg)
Limitations of the use of GFP transgenic mice in bone marrow transplantation studies.
; Delgaudine, Marie ; Beguin, Yves et al
in Leukemia & Lymphoma (2006), 47(7), 1392-3Detailed reference viewed: 52 (6 ULg)
Ac-SDKP: linking cardiac remodelling to haematological malignancies.
Caers, Jo ;
in Leukemia & Lymphoma (2006), 47(9), 1732-3Detailed reference viewed: 15 (0 ULg)
Relapsing T-cell lymphoma mimicking adult respiratory distress syndrome and sepsis.
; LAYIOS, Nathalie ; et al
in Leukemia & Lymphoma (2006), 47(9), 1989-90Detailed reference viewed: 7 (0 ULg)
Binding and migration across fibronectin and VCAM-1 of cycling hematopoietic progenitor cells.
Gothot, André ; Giet, Olivier ; et al
in Leukemia & Lymphoma (2003), 44(8), 1379-83
Using different experimental approaches, it has been established that transplantability of hematopoietic/stem progenitor cells is ineffective during transit through the cell cycle. Although primitive stem ... [more ▼]
Using different experimental approaches, it has been established that transplantability of hematopoietic/stem progenitor cells is ineffective during transit through the cell cycle. Although primitive stem cells are responsive to mitogenic stimulation in optimized ex vivo conditions, defective engraftment of generated cells may limit their detection in standard transplantation models as well as their use in clinical cell therapy. The activation level of adhesion receptors is modulated by stimulation of cytokine receptors via "inside-out" signaling. This prompted us to study the interactions of progenitor cells with fibronectin (Fn) in different phases of the cell cycle. We first demonstrated that adhesion to Fn was stimulated in S/G2 + M as compared to G0/G1, in ex vivo cultured CD34+ cells, with a predominant usage of very late antigen (VLA)-5 over that of VLA-4. We next determined that maximal Fn binding in active phases of the cell cycle limited cell motility toward stromal cell-conditioned medium. It was also observed that VLA-4 and VLA-5 ability to mediate adhesion or migration varied independently during cell cycle transit. Finally, in synchronized progenitor cells executing a first cell cycle ex vivo, a reversible increase in Fn binding was associated with a reversible decrease in adhesion to vascular cell-adhesion molecule (VCAM)-1. Overall, these observations suggest that defective engraftment of cycling stem/progenitor cells may result, at least in part, from abnormal trafficking related to changes in the activation level of adhesion receptors. [less ▲]Detailed reference viewed: 38 (3 ULg)
A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes.
Tassin, Françoise ; Dewé, Walthère ; Schaaf, Nicole et al
in Leukemia & Lymphoma (2000), 36(5-6), 485-96
Marrow dysplasia is a major characteristic of patients with myelodysplastic syndrome (MDS), along with marrow blastosis, cytopenia and cytogenetic anomalies. However, the impact of the degree of marrow ... [more ▼]
Marrow dysplasia is a major characteristic of patients with myelodysplastic syndrome (MDS), along with marrow blastosis, cytopenia and cytogenetic anomalies. However, the impact of the degree of marrow dysplasia on survival has not been fully assessed. In this retrospective analysis of 111 patients selected according to the IPSS criteria of MDS diagnosis, the presence or absence of 21 dysplasia characteristics recognizable in bone marrow smears stained by the May-Grunwald-Giemsa method was correlated with patient survival. Using Cox proportional hazards regression analysis, megaloblastosis (MEGALO), neutrophil agranularity (AGRAN) and hypogranularity (HYPOGRAN) were highly significant predictors (p < 0.005), and Pelger-Huet anomaly (PELGHUET) a significant predictor (p = 0.05), of patient survival. The regression analysis yielded a dysplasia-based risk index (DI) where DI = 1.26 MEGALO + 0.82 AGRAN - 1.08 HYPOGRAN + 0.45 PELGHUET. The two subgroups of 60 and 47 patients with DI < or = 0 and > 0 showed highly significant differences in median survivals (2.6 vs 1.1 yrs; p <0.0001). Multivariate analysis further showed that DI offered additional predictive power that was independent of that provided by the IPSS (p=0.002 and 0.001 respectively). Analysis of survival curves stratified for IPSS and DI showed that the additional predictive power offered by inclusion of the DI essentially concerned the IPSS low/INT-1 risk categories. Further stratification for age did not improve survival prediction. The data indicate that a set of 4 dysplasia parameters can offer some prediction for survival of MDS patients in addition to that provided by the IPSS. Further multicenter studies should aim at including some form of evaluation of the degree of dysplasia in prognostic systems. [less ▲]Detailed reference viewed: 50 (9 ULg)
Erythropoiesis and erythropoietin in multiple myeloma.
in Leukemia & Lymphoma (1995), 18(5-6), 413-21
In this review, the pathophysiology and treatment of the anemia of multiple myeloma will be examined. While the anemia of cancer has multiple causes, an important component is labeled the "anemia of ... [more ▼]
In this review, the pathophysiology and treatment of the anemia of multiple myeloma will be examined. While the anemia of cancer has multiple causes, an important component is labeled the "anemia of chronic disease" which is characterized by the combination of a shortened erythrocyte survival with failure of the bone marrow to increase red cell production in compensation. Depressed erythropoiesis is itself related to a combination of factors, including impaired availability of storage iron, inadequate erythropoietin response to anemia, and overproduction of cytokines which are capable of inhibiting erythropoiesis. These cytokines are involved in the retention of iron in the reticuloendothelial system, gastrointestinal tract and hepatocytes, may interfere with erythropoietin production by the kidney, and may exert direct inhibitory effects on erythroid precursors. While overproduction of several such cytokines, including IL-6, IL-1 and TNF-alpha, has been definitely demonstrated in multiple myeloma patients, it is still unclear whether they are directly involved in the pathogenesis of the anemia which develops. Although several mechanisms, such as hemodilution, bleeding, and decreased red cell survival operate, the anemia is mostly caused by defective erythropoietic activity. This in turn is partly explained by inadequate erythropoietin (Epo) production even in some patients without renal impairment. Based on measurements of serum erythropoietin and transferrin receptor, the distinction between marrow unresponsiveness to normal Epo stimulation and deficient Epo production is important for the treatment of the anemia of multiple myeloma with recombinant human Epo. Higher doses would probably be necessary if adequate Epo production is present, whereas only replacement therapy with lower doses may be sufficient when Epo production has been shown to be inappropriate. [less ▲]Detailed reference viewed: 32 (3 ULg)